Tianjin Anhao Biotechnology Co., Ltd., the Chinese subsidiary of U.S.-based GLSyntech, is an innovative drug development enterprise focused on establishing a quasi-drug compound technology platform and advancing the research and development of novel pharmaceuticals. Leveraging the technology, market presence, and customer base of its U.S. parent company, GLSyntech, it designs and synthesizes unique quasi-drug compounds through expert input. These compounds have already been commercialized with renowned multinational pharmaceutical companies, including Roche, GSK, Abbott, Novartis, Pfizer, Johnson & Johnson, Amgen, and Bayer, establishing a prestigious international clientele. The team possesses extensive global professional experience and innovation capabilities, with key technical members having over a decade of experience in new drug development at international multinational pharmaceutical corporations. The company excels in applying technologies such as drug target research, molecular drug design, lead compound synthesis, optimization of drug synthesis, and template design to rapidly transform patented technologies into new drug precursors and active pharmaceutical ingredients. Its current focus is on expanding the scale of research, development, and sales to lay the groundwork for future new drug development. We are an internationally compliant and dynamic enterprise that embraces challenges while emphasizing teamwork. Our goal is to establish China's largest and most technologically advanced quasi-drug compound library adhering to international standards. Innovation in drug development prioritizes anti-cancer and oncology drugs, central nervous system agents, anti-obesity medications, and anti-liver cancer therapeutics. We aim to list on the Growth Enterprise Market within approximately five years.